Peter Harrison, MA, (D.O.B. 1958), Chief Executive Officer
Peter Harrison has worked in the field of antibody technology since 1986 and has extensive experience of the development and commercialisation of antibody technologies. He graduated in Natural Sciences from Clare College Cambridge in 1980 and joined the graduate training scheme at Shell Chemicals UK Ltd. In 1986 he joined Celltech Ltd to manage their contract antibody production business and in 1991 he joined KS Biomedix Ltd and helped to establish sheep monoclonal antibody technology at their Farnham research laboratory. Following the acquisition of KS Biomedix Limited by Xenova plc in 2003, he led a management buy-out that resulted in the formation of Bioventix and he has led the subsequent commercial development of the Company.
Ian Nicholson, BSc, MBA, (D.O.B 1960) Non-Executive Chairman
Ian Nicholson was appointed as Non-Executive Chairman of Bioventix in November 2004. Ian is also currently Chief Executive Officer of F2G Ltd, a UK-based antifungal drug discovery and development company, a Non-executive Director of Consort Medical plc, a medical devices company and Clinigen Group plc, a specialty pharmaceuticals and services business and also an Operating Partner at Advent Life Sciences LLP. From 2004 to 2012 Ian was Chief Executive of Chroma Therapeutics Limited, a drug discovery and development company and from 2000 to 2004 Ian was Senior Vice President, Business Development at Celltech Group plc, then the UK’s largest biotechnology company. He has extensive experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US. Ian is a member of the Remuneration Committee.
Nick McCooke, (D.O.B 1953) Non-executive Director
Nick McCooke has worked in the biotech industry for over 30 years and is now an independent consultant providing operational, strategic and commercial advice and hands-on support to biotech companies. He has led several successful companies. He was the founding CEO of Solexa, the Cambridge University spin-out where he built the team that invented and developed Next Generation DNA Sequencing, leading to the recently announced $1000 human genome scan. More recently he was CEO of Belgian company Pronota, which is translating novel protein biomarkers into diagnostics, and where he gained much knowledge and expertise in the diagnostic development and market access process. He has an MBA from the London Business School.
Treena Turner, FCA, Finance Director
Treena is a qualified Chartered Accountant, and is a partner in a seven partner firm, Wise & Co based in Farnham. She has a wide range of experience of dealing with clients of all sizes and from varied business sectors. Covering a range of financial activities including accounts preparation and auditor liaison, Treena has worked closely with Bioventix since its incorporation in 2003 following the management buyout from KS Biomedix Limited.